Application of melatonin to preparation of medicine for treating autoimmune prostatitis and medicine for treating autoimmune prostatitis
An autoimmune, prostatitis technology, applied in the field of pharmaceutical applications, can solve problems such as unsatisfactory treatment methods for patients and doctors, and unclear etiology
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
preparation example Construction
[0022] In the present invention, the source of the melatonin is not particularly limited, and commercially available products well known in the art will suffice. In the present invention, the melatonin is used in the form of injection, and the preparation method of the injection of melatonin comprises: dissolving melatonin in dimethyl sulfoxide, mixing the resulting solution with normal saline, Get melatonin injections.
[0023] In the present invention, the mass concentration of the solution obtained by dissolving melatonin in dimethyl sulfoxide is preferably 0.1-0.2%; Salt water will do. The present invention has no special limitation on the mixing process of the obtained solution and physiological saline, as long as the materials can be mixed uniformly according to the well-known process in the art.
[0024] In the present invention, the concentration of melatonin in the melatonin injection is preferably 3-8 mg / mL, more preferably 4-6 mg / mL. In the present invention, the...
Embodiment 1
[0050] (1) The mouse model of autoimmune prostatitis was established by subcutaneously injecting the mixture of prostate antigen and complete Freund's adjuvant (volume ratio 1:1) into non-obese diabetic mice (NOD) on day 0 and day 28 ( EAP);
[0051] (2) Preparation of melatonin injection 8 mg / mL: 0.008 g of melatonin was dissolved in 0.05 mL of dimethyl sulfoxide, and the resulting solution (mass concentration: 0.16%) was mixed with 0.95 mL of normal saline to obtain melatonin Injection;
[0052] (3) From the 28th day of subcutaneous immunization, 0.2 mL melatonin injection was intraperitoneally injected into the EAP mice at 8-9 o'clock every morning (once a day, the total injection volume was 80 mg / kg / d) until the 28th day. The mice were sacrificed on day 42; the degree of inflammation was evaluated according to histopathology, EAP mouse plantar pain measurement, and peripheral blood ELISA detection, and then NLRP3, ASC, caspase-1, IL -Expression of 1β and Sirt1.
Embodiment 2
[0054] (1) The mouse model of autoimmune prostatitis was established by subcutaneously injecting the mixture of prostate antigen and complete Freund's adjuvant (volume ratio 1:1) into non-obese diabetic mice (NOD) on day 0 and day 28 ( EAP);
[0055] (2) Use the melatonin injection 8 mg / mL prepared in Example 1, and simultaneously prepare the Sirt1 inhibitor-EX527 injection 0.5 mg / mL: 0.0005 g EX527 is dissolved in 0.05 mL dimethyl sulfoxide, and the resulting solution ( The mass concentration is 0.1%) mixed with 0.95mL physiological saline to obtain Sirt1 inhibitor-EX527 injection;
[0056] (3) From the 28th day of subcutaneous immunization, intraperitoneally inject melatonin injection (once a day, the volume of each injection is 0.2 mL, and the total daily injection volume is 80 mg / kg) to EAP mice at 8 to 9 o'clock every morning. / d), until the mice were killed on the 42nd day;
[0057] (4) From the day before melatonin injection, intraperitoneally inject Sirt1 inhibitor-E...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com